$475 million acquisition of Metrics Contract Services by Catalent Inc.
Catalent Inc. is set to acquire Metrics Contract Services in a USD $475 million bid to expand its high-potent capacities and oral development and manufacturing capabilities by the end of 2022
Drug and healthcare solutions provider Catalent Inc. have announced their plans to acquire full-service CDMO Metrics Contract Services to bolster its capabilities for integrated oral solid formulation development, manufacturing, and packaging.
The USD $475 million acquisition, which includes a facility in Greenville, North Carolina to join Catalent’s headquarters in Somerset, New Jersey, will also expand Catalent’s capacity in handling high-potent compounds. The Greenville facility expands over 333,000 square-feet and is designed with comprehensive acceleration and development capabilities for early drug development through to commercial launch programs. With over USD $100 million in improvements over the last 5 years and 16 manufacturing suites, 11 of which are designed to handle highly potent compounds, the facility's annual production capacity is estimated to exceed 1 billion oral solid dose units. Catalent hopes the acquisition will strengthen their efforts to meet customer expectations in simplifying and accelerating development and manufacturing programs.
Group President of Catalent’s Pharma & Consumer Health segment Aris Gennadios commented: “This acquisition will further expand Catalent’s ability to meet our customers’ expectations in fast-growing areas of the business and patient need. The experienced team and consistently improved, state-of-the-art facility in Greenville will provide Catalent’s customers with immediate, fit-for-scale capacity for in-demand highly potent drugs and other oral solid small-to-mid-size batch needs. This capacity is particularly important for customers with R&D pipelines featuring accelerated, orphan, and rare disease programs for oncology and other important therapeutic areas.”
Scott Richards, CEO of Mayne Pharma, added: “Over the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid CDMO. Catalent, a global leader in advanced drug development and manufacturing, is well-positioned to continue to invest in and accelerate the growth of Metrics and we believe this transaction will be extremely positive for our Greenville team and customers.”
The acquisition is expected to be closed before the end of 2022, adding a team of over 400 employees to Catalent.
Source: Catalent to Acquire Metrics Contract Services for $475 Million
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance